Vtv Theraptcs Cl A (VTVT)

$14.05 +0.01 (0.04%)
Market Cap 44.81M
Revenue (ttm) 0.00
Net Income (ttm) -20.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,300
Avg Vol 30,664
Day's Range N/A - N/A
Shares Out 3.19M
Stochastic %K 41%
Beta 0.69
Analysts Strong Buy
Price Target $35.00

Latest News on VTVT

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 9, 2024, 7:33 AM EST - 5 weeks ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Dec 2, 2024, 4:05 PM EST - 6 weeks ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2024, 4:15 PM EDT - 5 months ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jul 26, 2024, 4:05 PM EDT - 6 months ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

Jun 24, 2024, 4:05 PM EDT - 7 months ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 28, 2024, 8:00 AM EDT - 8 months ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

May 9, 2024, 4:51 PM EDT - 9 months ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 19, 2024, 8:30 AM EDT - 10 months ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 13, 2024, 8:00 AM EDT - 11 months ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 4, 2024, 8:00 AM EST - 11 months ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Mar 1, 2024, 8:00 AM EST - 11 months ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 28, 2024, 8:00 AM EST - 11 months ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Feb 22, 2024, 4:00 PM EST - 11 months ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 9, 2023, 4:30 PM EST - 1 year ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 1 year ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 2, 2023, 8:00 AM EDT - 1 year ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Nov 1, 2023, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Sep 27, 2023, 8:30 AM EDT - 1 year ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 26, 2023, 8:30 AM EDT - 1 year ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Sep 18, 2023, 8:30 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 11, 2023, 4:30 PM EDT - 1 year ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Aug 10, 2023, 8:33 AM EDT - 1 year ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 16, 2023, 8:00 AM EDT - 1 year ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

Jun 15, 2023, 7:33 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 24, 2023, 9:00 AM EDT - 1 year ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 11, 2023, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Apr 20, 2023, 8:00 AM EDT - 1 year ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 5:56 PM EST - 2 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Mar 6, 2023, 8:02 AM EST - 2 years ago

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Feb 27, 2023, 8:02 AM EST - 2 years ago

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

Feb 1, 2023, 5:00 PM EST - 2 years ago

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Jan 9, 2023, 8:00 AM EST - 2 years ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Dec 13, 2022, 8:15 AM EST - 2 years ago

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

Nov 10, 2022, 5:25 PM EST - 2 years ago

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

Aug 15, 2022, 6:43 PM EDT - 2 years ago

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer

Jul 27, 2022, 7:00 AM EDT - 2 years ago

vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer

vTv Therapeutics Announces Investment by CinRx Pharma

Jul 25, 2022, 7:00 AM EDT - 2 years ago

vTv Therapeutics Announces Investment by CinRx Pharma

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Jun 4, 2022, 11:00 AM EDT - 2 years ago

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

Jun 1, 2022, 6:54 AM EDT - 2 years ago

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update

May 12, 2022, 7:45 AM EDT - 2 years ago

vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 29, 2022, 9:47 PM EDT - 3 years ago

vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces CEO Transition

Mar 3, 2022, 8:48 PM EST - 3 years ago

vTv Therapeutics Announces CEO Transition

vTv Therapeutics Shares Updated Corporate Presentation

Jan 13, 2022, 8:30 AM EST - 3 years ago

vTv Therapeutics Shares Updated Corporate Presentation

vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%

Dec 7, 2021, 5:43 AM EST - 3 years ago

vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%

vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations

Dec 6, 2021, 5:19 PM EST - 3 years ago

vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations

vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update

Nov 9, 2021, 8:30 AM EST - 3 years ago

vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Deepa Prasad as New President and CEO

Oct 20, 2021, 9:00 AM EDT - 3 years ago

vTv Therapeutics Announces Deepa Prasad as New President and CEO

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Oct 12, 2021, 7:30 AM EDT - 3 years ago

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

vTv Therapeutics Stock Gains As Psoriasis Candidate Shows Favorable Safety Profile

Sep 24, 2021, 6:50 AM EDT - 3 years ago

vTv Therapeutics Stock Gains As Psoriasis Candidate Shows Favorable Safety Profile